Reported Earlier, Vaxcyte Prices 7,412,500 Common Shares At $64.00 Each, 400,000 Pre-Funded Warrants And $500M 1.50% Convertible Notes Due 2032 In Concurrent Offerings
Share
Why It Matters
Vaxcyte raised money by selling new shares and special bonds to investors. This gives the company cash to spend, so watch if they use it well on their vaccine work.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.